We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Bayer (BAYRY) Stock Moves -1.33%: What You Should Know
Read MoreHide Full Article
Bayer (BAYRY - Free Report) closed the most recent trading day at $17.02, moving -1.33% from the previous trading session. This change lagged the S&P 500's daily of 0%. Meanwhile, the Dow lost 0.05%, and the Nasdaq, a tech-heavy index, lost 0.21%.
Prior to today's trading, shares of the drug and chemical company had lost 10.2% over the past month. This has lagged the Medical sector's gain of 1.69% and the S&P 500's gain of 5.49% in that time.
Investors will be hoping for strength from BAYRY as it approaches its next earnings release. On that day, BAYRY is projected to report earnings of $0.47 per share, which would represent a year-over-year decline of 31.88%.
Any recent changes to analyst estimates for BAYRY should also be noted by investors. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. The Zacks Consensus EPS estimate remained stagnant within the past month. BAYRY currently has a Zacks Rank of #2 (Buy).
In terms of valuation, BAYRY is currently trading at a Forward P/E ratio of 8.85. Its industry sports an average Forward P/E of 15.27, so we one might conclude that BAYRY is trading at a discount comparatively.
Investors should also note that BAYRY has a PEG ratio of 0.85 right now. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. BAYRY's industry had an average PEG ratio of 2.09 as of yesterday's close.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 64, which puts it in the top 26% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Bayer (BAYRY) Stock Moves -1.33%: What You Should Know
Bayer (BAYRY - Free Report) closed the most recent trading day at $17.02, moving -1.33% from the previous trading session. This change lagged the S&P 500's daily of 0%. Meanwhile, the Dow lost 0.05%, and the Nasdaq, a tech-heavy index, lost 0.21%.
Prior to today's trading, shares of the drug and chemical company had lost 10.2% over the past month. This has lagged the Medical sector's gain of 1.69% and the S&P 500's gain of 5.49% in that time.
Investors will be hoping for strength from BAYRY as it approaches its next earnings release. On that day, BAYRY is projected to report earnings of $0.47 per share, which would represent a year-over-year decline of 31.88%.
Any recent changes to analyst estimates for BAYRY should also be noted by investors. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. The Zacks Consensus EPS estimate remained stagnant within the past month. BAYRY currently has a Zacks Rank of #2 (Buy).
In terms of valuation, BAYRY is currently trading at a Forward P/E ratio of 8.85. Its industry sports an average Forward P/E of 15.27, so we one might conclude that BAYRY is trading at a discount comparatively.
Investors should also note that BAYRY has a PEG ratio of 0.85 right now. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. BAYRY's industry had an average PEG ratio of 2.09 as of yesterday's close.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 64, which puts it in the top 26% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.